Pharmaceutical

Left in limbo: When pharma halts rare disease research

Academic institutions and nonprofit organisations are jumping in to save access to complex gene therapies.

Jul 4, 2024 - 04:00
Left in limbo: When pharma halts rare disease research
Academic institutions and nonprofit organisations are jumping in to save access to complex gene therapies.
Read the original article

Tags:

Previous Article

Moderna’s mRNA influenza vaccine receives $176m boost

Next Article

Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer

Oncoinvent’s Radspherin has FDA fast-track status for o...

Jun 26, 2024

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a h...

Dec 9, 2023

Opinion: Millions of people take birth control to treat endometriosis — but it doesn’t work

Opinion: Millions of people take birth control to treat...

Apr 5, 2023